Joel Greenblatt’s Syndax Pharmaceuticals SNDX Stock Holding History

Joel Greenblatt’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-48,246	Closed	-$742K	–	1818
2025 Q3	$742K	Buy	+48,246	New	+$631K	﹤0.01%	1289
2021 Q1	–	Sell	-7,413	Closed	-$749K	–	1084
2020 Q4	$749K	Buy	+7,413	New	+$154K	0.02%	616

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Joel Greenblatt's SNDX Position: Q4 2025 in Review

Joel Greenblatt sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 48,246 shares — an estimated $742K sold.

Joel Greenblatt first reported a position in SNDX in Q4 2020 and held it in 2 quarters. The position peaked at $749K in Q4 2020. 230 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Joel Greenblatt reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Joel Greenblatt sold 48,246 Syndax Pharmaceuticals shares in Q4 2025, an estimated $742K.
Joel Greenblatt first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Joel Greenblatt's Syndax Pharmaceuticals position peaked at $749K in Q4 2020.
230 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Gotham Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.